Sponsors › Amgen

Amgen

Every GLP‑1 and incretin trial, approval and scheduled result we hold for Amgen, drawn from ClinicalTrials.gov and Drugs@FDA.

Amgen is a commercial sponsor with 15 trials in the incretin class on file here, across 2 molecules. The programme is split between 3 early-stage trials and 12 in phase 3 or later. No approved FDA submission is recorded against this sponsor for these molecules, which is normal for a programme that has not reached the market. The next scheduled result is 2027-01-21.

Molecules: maridebart cafraglutide · semaglutide
Trials on file: 15
Active trials: 14
Results scheduled: 13
Approved FDA submissions: 0

Results due

Est. completion	Drug	Trial	Phase	Participants
2027-01-21	maridebart cafraglutide	Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight NCT06858839	P3	3,853
2027-01-21	maridebart cafraglutide	Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight NCT06858878	P3	1,105
2027-04-27	maridebart cafraglutide	Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease NCT06987695	P3	279
2027-06-16	maridebart cafraglutide	Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight NCT07871409	P3	230
2027-08-20	maridebart cafraglutide	Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy NCT07225686	P3	250
2027-08-25	maridebart cafraglutide	A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight NCT07441252	P2	180
2027-08-30	maridebart cafraglutide	Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy NCT07226765	P3	250
2027-12-26	maridebart cafraglutide	Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) NCT07684144	P3	950
2027-12-26	maridebart cafraglutide	Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) NCT07684235	P3	3,200
2028-01-03	maridebart cafraglutide	Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) NCT07575399	P3	300
2028-06-30	maridebart cafraglutide	Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity NCT07037433	P3	12,800
2028-06-30	maridebart cafraglutide	Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity NCT07037459	P3	5,056
2028-09-04	semaglutide	Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes NCT07866066	P3	1,300

Trials on file

All 15 incretin trials recorded for this sponsor, active first.

Drug	Trial	Status	Phase	Participants
maridebart cafraglutide	Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity NCT07037433	Recruiting	P3	12,800
maridebart cafraglutide	Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity NCT07037459	Recruiting	P3	5,056
maridebart cafraglutide	Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight NCT06858839	Active, not recruiting	P3	3,853
maridebart cafraglutide	Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) NCT07684235	Recruiting	P3	3,200
semaglutide	Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes NCT07866066	Not yet recruiting	P3	1,300
maridebart cafraglutide	Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight NCT06858878	Active, not recruiting	P3	1,105
maridebart cafraglutide	Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) NCT07684144	Recruiting	P3	950
maridebart cafraglutide	A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM) NCT06660173	Active, not recruiting	P2	409
maridebart cafraglutide	Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) NCT07575399	Recruiting	P3	300
maridebart cafraglutide	Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease NCT06987695	Active, not recruiting	P3	279
maridebart cafraglutide	Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy NCT07225686	Active, not recruiting	P3	250
maridebart cafraglutide	Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy NCT07226765	Active, not recruiting	P3	250
maridebart cafraglutide	Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight NCT07871409	Not yet recruiting	P3	230
maridebart cafraglutide	A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight NCT07441252	Active, not recruiting	P2	180
maridebart cafraglutide	Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus NCT05669599	Completed	P2	592